Skip to main content

Treatment Clinical Trials for Thyroid Cancer

Review the thyroid cancer treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Study of Targeted Therapy vs. Chemotherapy in Patients with Thyroid Cancer
Status: Active
Location: 296 locations
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Status: Active
Location: 16 locations
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
Status: Active
Location: 12 locations
Study of PYX-201 in Solid Tumors
Status: Active
Location: 9 locations
A Study of Avutometinib and Defactinib in Patients with Thyroid Cancer
Status: Active
Location: 8 locations
Dabrafenib, Trametinib, and IMRT in Treating Patients with BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Active
Location: 5 locations
SLV-154 Treatment of Metastatic Solid Tumors
Status: Active
Location: 5 locations
Cyclophosphamide and Sirolimus and in Treating Patients with Metastatic, Radioiodine-Refractory Thyroid Cancer
Status: Active
Location: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Treatment of Pembrolizumab in Metastatic or Unresectable Anaplastic/Undifferentiated Thyroid Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Vemurafenib and Cobimetinib for the Treatment of Patients with High Risk Differentiated Thyroid Carcinoma with BRAFV600E Mutation
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Lower Dose Versus Standard Dose Lenvatinib for the Treatment of Symptomatic or Progressive Radioactive Iodine Resistant Differentiated Thyroid Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Selpercatinib Prior to Radioiodine Therapy for the Treatment of Children, Adolescents, and Young Adults with Metastatic Differentiated Thyroid Cancers that Harbor a RET Fusion, RAISE Trial
Status: Active
Location: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Radiation Therapy and Radioactive Iodine for the Treatment of Recurrent Papillary or Follicular Thyroid Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
XL092 and Cemiplimab for the Treatment of BRAF V600E-Wild Type Anaplastic Thyroid Cancer, NEO-COMBAT XL Trial
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Stereotactic MRI-Guided Focused Ultrasound Mesencephalotomy for Pain Palliation in Head & Neck Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer
Status: Active
Location: See ClinicalTrials.gov
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas